Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2006
Headquarters: Franklin Lakes, New Jersey
BD is a global medical technology company operating through three segments: BD Medical (injection, infusion, and surgery products), BD Diagnostics (specimen collection and infectious disease testing), and BD Biosciences (research and clinical tools). The company serves healthcare institutions, life science researchers, and the general public worldwide.
Key Financial Metrics
Note: Detailed revenue, profit, cash flow, and margin figures are incorporated by reference from the Annual Report to Shareholders (Exhibit 13) and are not explicitly stated in the provided text.
- Research & Development (R&D): $360 million for fiscal 2006 (up from $272 million in 2005 and $236 million in 2004). This included a $53 million in-process R&D charge related to the GeneOhm acquisition.
- Employee Count: 26,990 employees as of September 30, 2006 (12,288 in the U.S.).
- Stock Repurchases: 235,499 shares purchased in the quarter ended September 30, 2006, at an average price of $70.24 per share. Approximately 7.06 million shares remained available for purchase under the 2005 Program.
- Valuation Accounts: Allowance for doubtful accounts decreased from $33.4 million to $28.4 million; allowance for cash discounts decreased from $14.2 million to $9.8 million.
- International Exposure: Over half of fiscal 2006 revenues were derived from international operations.
Material Changes and Strategic Actions
- Acquisitions:
- Acquired GeneOhm Sciences, Inc. (February 2006) to expand into molecular diagnostic testing for healthcare-associated infections.
- Announced agreement to acquire remaining 93.5% of TriPath Imaging (September 2006) to enhance cancer diagnostic capabilities; expected to close in Q1 2007.
- Divestiture/Exit: Announced exit from the blood glucose monitoring market (September 2006), discontinuing the BD Logic Blood Glucose Monitor. Test strip distribution will continue through December 2007.
- Regulatory Action: Received an FDA warning letter in November 2006 regarding compliance with Current Good Manufacturing Practice requirements at the San Lorenzo, Puerto Rico facility.
- Legal Proceedings: Named defendant in multiple antitrust class actions (direct and indirect purchasers) and product liability suits (needlestick injuries, latex gloves). Antitrust cases are consolidated in Multi-District Litigation (MDL) in New Jersey.
Outlook, Risks, and Contingencies
Management Commentary & Outlook: BD's strategy focuses on revenue growth through products delivering greater benefits to patients and researchers. The company anticipates continued investment in R&D, quality management, and productivity. Management believes disclosure controls and procedures were effective as of September 30, 2006.
Key Risks:
- Regulatory & Compliance: Extensive regulation by the FDA and foreign agencies; potential for product recalls, seizures, or sanctions. Recent FDA warning letter requires a response plan.
- Legal & Litigation: Significant exposure to antitrust claims alleging price-fixing and product liability claims. Outcomes are uncertain and could result in material charges.
- Market & Competition: Intense competition, pricing pressure from group purchasing organizations (GPOs), and potential obsolescence due to new technologies (e.g., inhaled insulin).
- Supply Chain: Reliance on sole-source suppliers for certain raw materials (primarily BD Biosciences) creates risk of supply interruption.
- Foreign Operations: Exposure to foreign currency exchange fluctuations, political instability, and trade barriers.
- UN Oil-for-Food Inquiry: A subsidiary (BD-France) was listed in a UN report regarding suspected unauthorized payments to the Iraqi Government. BD's internal review found no evidence of improper payments by BD or its employees.
Investor Verification Checklist
- Verify the full financial impact of the GeneOhm acquisition and the pending TriPath Imaging acquisition on future earnings and cash flow.
- Review the specific financial statements in Exhibit 13 for exact revenue, net income, and operating margin figures, as they are not detailed in the main text.
- Monitor the status of the FDA warning letter response and any potential impact on the Puerto Rico manufacturing facility's operations.
- Assess the potential financial liability from consolidated antitrust litigation and product liability suits.
- Confirm the timeline and financial implications of the exit from the blood glucose monitoring market.
- Review the "Financial Review" section in Exhibit 13 for detailed analysis of foreign currency exchange impacts on profitability.